A biotechnology company developing treatments for Adrenomyeloneuropathy , Human Immunodeficiency Virus Nutra Pharma Drug Discovery subsidiary Novel Antiviral Therapy at the International AIDS Conference in Vienna, Austria,) introduce multiple sclerosis and pain, announced that its drug discovery subsidiary ReceptoPharm at the International at the International AIDS Conference in Vienna, Austria get information yourbeautyph.com .
The focus of ReceptoPharm presentation on a novel antiviral therapy PEPTERON that is based on the company’s lead drug candidate, RPI – MN. RPI – MN has been shown by the entry of several viruses known to cause severe neurological damage in such diseases as encephalitis and inhibit HIV. The presentation will be given by Dr. Dorothy Bray, who serves on the Scientific Advisory Board ReceptoPharm. Previously, Dr. Bray as director of the HIV Clinical Development at GlaxoSmithKline with global responsibility for their clinical trials program. GSK is currently one of the largest providers of HIV antiretroviral drugs. – ‘We are excited to have this opportunity to introduce our antiviral therapy PEPTERON at the International AIDS Conference,’commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. ‘As we move our HIV clinical development program, we are actively seeking international collaborations and partnerships that will help our ability to utilize PEPTERON through the approval procedure intend to bring,’he said.
Some of the activities are described in this press release, funded by the American Recovery and Reinvestment Act of 2009 -. Longer information on ARRA funding on healthcare professionals can be found here.